GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (HKSE:09969) » Definitions » 5-Year Yield-on-Cost %

InnoCare Pharma (HKSE:09969) 5-Year Yield-on-Cost % : 0.00 (As of Dec. 15, 2024)


View and export this data going back to 2020. Start your Free Trial

What is InnoCare Pharma 5-Year Yield-on-Cost %?

InnoCare Pharma's yield on cost for the quarter that ended in Jun. 2024 was 0.00.


The historical rank and industry rank for InnoCare Pharma's 5-Year Yield-on-Cost % or its related term are showing as below:



HKSE:09969's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.57
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of InnoCare Pharma's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, InnoCare Pharma's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnoCare Pharma's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InnoCare Pharma's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where InnoCare Pharma's 5-Year Yield-on-Cost % falls into.



InnoCare Pharma 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of InnoCare Pharma is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

InnoCare Pharma  (HKSE:09969) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


InnoCare Pharma 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCare Pharma Business Description

Traded in Other Exchanges
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
Executives
The Goldman Sachs Group, Inc. 2201 Interest of corporation controlled by you
Cui Jisong
King Bridge Investments Limited 2101 Beneficial owner
Pang Kee Chan Hebert 2201 Interest of corporation controlled by you
Shi Yigong
Zhao Renbin
Sunny View Holdings Limited
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Hhlr Fund, L.p. 2101 Beneficial owner
Highbury Investment Pte Ltd 2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd. 2102 Investment manager
Tmf (cayman) Ltd. 2301 Trustee
Sunland Biomed Ltd 2101 Beneficial owner

InnoCare Pharma Headlines

No Headlines